Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin on Central Blood Pressure Reduction Compared to Glimepiride in T2DM
NCT02919059Phase 4Unknown
- Sponsor
- Instituto Gallego de Medicina Vascular
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Instituto Gallego de Medicina Vascular. Primary endpoint: Central Systolic Blood Pressure at 24 weeks. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02919059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919059.